Brunilda Shtylla

Kivu Bioscience, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, has appointed Brunilda Shtylla as Chief Business Officer. 

In her new role, Shtylla will lead corporate strategy, business development, and partnership initiatives as the company advances its ADC pipeline and expands strategic collaborations.

Shtylla brings more than 25 years of experience across biotechnology, medical devices, finance, and strategic transactions. Most recently, she served as Chief Business Officer at Sutro Biopharma, where she led business strategy and development efforts that supported collaborations, licensing deals, and partnerships, helping secure more than US$5.5 billion in total deal value.

Earlier in her career, she advised leading organizations including Genentech, GRAIL, and Edwards Lifesciences, and held leadership roles at LifeScan, a Johnson & Johnson company. Shtylla holds an MBA from Stanford Graduate School of Business, an MS in Mathematics from Youngstown State University, and a BS in Business from Wayne State University.